Long-term Outcome of a Successful Cord Blood Stem Cell Transplant in Mevalonate Kinase Deficiency
Overview
Authors
Affiliations
Mevalonate kinase deficiency (MKD) is a rare autosomal recessive inborn error of metabolism with an autoinflammatory phenotype that may be expressed as a spectrum of disease phenotypes, from those with prevailing autoinflammatory syndrome and variable response to anti-inflammatory therapies, to mevalonic aciduria, which is associated with dysmorphic features, severe neurologic involvement, and the worst prognosis. We describe a boy, aged 2 years, 10 months, with severe phenotype of mevalonate kinase deficiency who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical unrelated cord blood because his condition had failed to improve with antiinflammatory treatment as first-line therapy and an anticytokine drug as second-line therapy. The child had a sustained remission of febrile attacks and inflammation after transplant, and during a 5-year follow-up period, psychomotor and neurologic development were normal, without signs of underlying disease or late transplant-related effects. This case confirms that allogeneic HSCT is a safe and effective cure for patients affected by MKD in whom anticytokine drugs alone are insufficient for the management of autoinflammatory syndrome and for the unfavorable outcome of the disease.
The efficacy and safety of allogeneic stem cell transplantation in Mevalonate Kinase Deficiency.
Jeyaratnam J, Faraci M, Gennery A, Drabko K, Algeri M, Morimoto A Pediatr Rheumatol Online J. 2022; 20(1):56.
PMID: 35906690 PMC: 9338460. DOI: 10.1186/s12969-022-00716-4.
Kim H, Lee B, Do H, Kim G, Kang S, Koh K Front Immunol. 2021; 12:782780.
PMID: 34950147 PMC: 8691729. DOI: 10.3389/fimmu.2021.782780.
Compromised Protein Prenylation as Pathogenic Mechanism in Mevalonate Kinase Deficiency.
Politiek F, Waterham H Front Immunol. 2021; 12:724991.
PMID: 34539662 PMC: 8446354. DOI: 10.3389/fimmu.2021.724991.
Hematopoietic Cell Transplantation Ameliorates Autoinflammation in A20 Haploinsufficiency.
Shiraki M, Williams E, Yokoyama N, Shinoda K, Nademi Z, Matsumoto K J Clin Immunol. 2021; 41(8):1954-1956.
PMID: 34427832 DOI: 10.1007/s10875-021-01124-1.
Pisanti S, Citro M, Abate M, Caputo M, Martinelli R Int J Environ Res Public Health. 2021; 18(3).
PMID: 33525735 PMC: 7908123. DOI: 10.3390/ijerph18031170.